DOI:

Thirty-day outcomes after TAVI in patients with severe aortic stenosis and moderate or severe mitral regurgitation

Baumgartner H. on behalf of the SOURCE XT Investigators

Transcatheter therapies in patients with mitral regurgitation or poor left ventricular function

Thirty-day outcomes after TAVI in patients with severe aortic stenosis and moderate or severe mitral regurgitation

Aims: Moderate and severe mitral regurgitation (MR) is associated with higher mortality in patients with CHF, but little is known about its impact on outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI). Isolated surgical aortic valve replacement usually has a positive impact on functional MR but the effect of TAVI is not well understood. We sought to assess the effect of MR on early clinical outcomes after transcatheter SAPIEN XT valve (Edwards Lifesciences LLC, Irvine, CA, USA) implantation, and the impact of TAVR on MR.

Methods and results: SOURCE XT is a multicentre, prospective, post-approval study which enrolled >2,600 consecutive patients at 94 sites in 17 countries. Total of 968 patients (36.8%) did not have any MR at baseline, 1,144 patients (43.5%) were with mild MR, 461 patients (17.5%) were with moderate MR, and 56 patients (2.1%) were with severe MR. Patients with moderate or severe MR were included in the MR Group (MR-Gr, n=517) and those with none or mild MR were included in the control group (C-Gr, n=2,112). Compared to the C-Gr, patients in the MR-Gr were more likely to be older (82.3±5.4 vs. 81.6±5.9, p=0.0148), female (63.1% vs. 56.5%, p=0.0073) with NYHA III/IV (81.4 vs. 75.9%, p=0.0073) and greater STS score (10±8.3 vs. 8.1±6.6, p<0.0001). MR-Gr patients had significantly higher incidence of CHF, atrial fibrillation or renal insufficiency. Mean gradient was similar for the two groups (47.5±17.0 vs. 47.3±20.1 mmHg, p=0.81); however, EF was significantly lower (50.1±12.0% vs. 53.0±11.2%, p<0.0001) and pulmonary pressure was significantly higher (50.5±16.0 mmHg vs. 43.3±14.1 mmHg, p<0.0001) in MR-Gr vs. C-Gr. There were no significant differences between MR-Gr and C-Gr in terms of overall mortality (7.2% vs. 5.9%, p=0.28), cardiac death (2.5% vs. 2.2%, p=0.64), stroke (1.2% vs. 2.6%, p=0.0627), major vascular complications (1.4% vs. 1.9%, p=0.41) or major bleeding events (7.4% vs. 7.8%, p=0.81). One month after TAVI, MR had improved by at least 1 degree in 30.4% of patients with any MR at baseline and in 44% of patients with moderate or severe MR.

Conclusions: Despite significant comorbidity, TAVI in patients with severe aortic stenosis and concomitant moderate or severe MR was not associated with an increased mortality. Furthermore, MR was improved in 44% of patients but longer follow-up is needed to understand the potential benefit of TAVI in this subset of patients.

Volume 8 Supplement Q
Sep 30, 2012
Volume 8 Supplement Q
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-E-23-00020 Aug 21, 2023
Mitral regurgitation improvement after TAVI: if well planned, two birds are killed with one stone
Zamorano Gómez J and Pardo Sanz A
free

Clinical research

10.4244/EIJ-D-22-01062 Aug 21, 2023
Impact of mitral regurgitation aetiology on the outcomes of transcatheter aortic valve implantation
Doldi PM et al
free

Clinical Research

10.4244/EIJ-D-21-00784 May 15, 2022
Five-year outcomes of mild paravalvular regurgitation after transcatheter aortic valve implantation
Okuno T et al
free
Trending articles
309.93

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
166.7

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
92.2

State-of-the-Art Review

10.4244/EIJ-D-20-01296 Aug 27, 2021
Management of cardiogenic shock
Thiele H et al
free
76

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
72.85

State-of-the-Art

10.4244/EIJ-D-24-00386 Feb 3, 2025
Mechanical circulatory support for complex, high-risk percutaneous coronary intervention
Ferro E et al
free
58.3

Clinical research

10.4244/EIJ-D-23-00344 Sep 18, 2023
Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
Sanchez-Luna JP et al
free
56.65

Clinical research

10.4244/EIJ-D-20-01155 Oct 20, 2021
A deep learning algorithm for detecting acute myocardial infarction
Liu W et al
free
33.9

CLINICAL RESEARCH

10.4244/EIJ-D-17-00381 Oct 11, 2017
Stent malapposition and the risk of stent thrombosis: mechanistic insights from an in vitro model
Foin N et al
free
33.65

State-of-the-Art

10.4244/EIJ-D-23-00606 Jan 1, 2024
Targeting inflammation in atherosclerosis: overview, strategy and directions
Waksman R et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved